T1	Participants 137 173	patients undergoing cardiac surgery:
T2	Participants 892 1018	patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure.
T3	Participants 1774 1810	patients undergoing cardiac surgery.
